Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023241 (
Legionella
)
6,990
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Legionella
pneumophila causes community- and hospital-acquired pneumonia. Lung airway and alveolar epithelial cells comprise an important barrier against airborne pathogens. Cyclooxygenase (COX) and microsomal PGE(2) synthase-1 (mPGES-1)-derived prostaglandins like prostaglandin E(2) (PGE(2)) are considered as important regulators of lung function. Herein we tested the hypothesis that L. pneumophila induced
COX-2
and mPGES-1-dependent PGE(2) production in pulmonary epithelial cells.
Legionella
induced the release of PGE(2) in primary human small airway epithelial cells and A549 cells. This was accompanied by an increased expression of
COX-2
and mPGES-1 as well as an increased PLA(2) activity in infected cells. Deletion of the type IV secretion system Dot/Icm did not impair
Legionella
-related
COX-2
expression or PGE(2) release in A549 cells. L. pneumophila induced the degradation of IkappaBalpha and activated NF-kappaB. Inhibition of IKK blocked L. pneumophila-induced PGE(2) release and
COX-2
expression. We noted activation of p38 and p42/44 MAP kinase in
Legionella
-infected A549 cells. Moreover, membrane translocation and activation of PKCalpha was observed in infected cells. PKCalpha and p38 and p42/44 MAP kinase inhibitors reduced PGE(2) release and
COX-2
expression. In summary, PKCalpha and p38 and p42/44 MAP kinase controlled
COX-2
expression and subsequent PGE(2) release by
Legionella
-infected lung epithelial cells. These pathways may significantly contribute to the host response in
Legionnaires' disease
.
...
PMID:Legionella pneumophila-induced PKCalpha-, MAPK-, and NF-kappaB-dependent COX-2 expression in human lung epithelium. 1701 71